Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Stage-Based herbal therapy slow Alzheimer's decline?

NCT ID NCT07768579

Knowledge-focused Sponsor: Dongzhimen Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study follows 600 people aged 55 to 85 with early, middle, or late-stage Alzheimer's disease for 12 months. Researchers will track changes in memory, daily activities, behavior, and traditional Chinese medicine symptom patterns. They will also observe whether those receiving stage-based sequential traditional Chinese medicine show different outcomes and what side effects occur. The goal is to understand how the disease evolves and whether this personalized approach might help.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stage-based sequential traditional Chinese medicine treatment
What this could lead to
If successful, this could help tailor Alzheimer's care by showing whether stage-based traditional Chinese medicine improves memory, daily function, and quality of life.
What could go wrong
This is an observational study, not a controlled trial, so any benefits seen might be due to other factors. Also, traditional Chinese medicine can have side effects, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of participants with different stages of Alzheimer's disease recruited from Dongzhimen Hospital, Beijing University of Chinese Medicine, and participating study centers. Recruitment settings include brain disease departments, neurology departments, memory clinics, and traditional Chinese medicine outpatient clinics. Participants include individuals with mild cognitive impairment due to Alzheimer's disease and those with mild, moderate, or severe Alzheimer's dementia.

Ages

55 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 55 to 85 years, regardless of sex. * Memory decline reported by the participant or family member for at least 6 months. * Meets the diagnostic criteria for the target disease and is clinically diagnosed with mild cognitive impairment due to Alzheimer's disease or mild, moderate, or severe Alzheimer's dementia. * Able to complete clinical scale assessments and blood sampling. * Able to undergo brain magnetic resonance imaging (MRI) or amyloid-beta positron emission tomography (Aβ-PET) examinations using the tracers specified in the study protocol. * Written informed consent provided by the participant or a legally authorized representative. * Able to complete study follow-up. * Participants with a known allergy to components of the exposure medications will be assigned to the non-exposed group. Exclusion Criteria: * Cerebrovascular disease, traumatic brain injury, thyroid dysfunction, vitamin deficiency, or other diseases sufficient to cause cognitive impairment. * Malignant tumors unrelated to the target disease, hematological diseases, severe psychiatric disorders, depression, or anxiety disorders. * Severe dysfunction of major organs, including the heart, brain, liver, or kidneys. * Infectious diseases, including HIV or HBV infection. * Pregnancy, breastfeeding, or plans for pregnancy in the near future. * Gastrointestinal diseases that may affect drug absorption. * Use of medications affecting cognitive function within 4 weeks before enrollment. * Recent participation in or current participation in another trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Mild cognitive impairment due to Alzheimer disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dongzhimen Hospital, Beijing University of Chinese Medicine

    RECRUITING

    Beijing, Beijing Municipality, 100700, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.